The algae supplement was linked to significant increases in HDL cholesterol.
Researchers from Wayne State University observed cholesterol improvements in hamsters fed samples of ProAlgaZyme, a finished dietary supplement from Health Enhancement Products Inc. Results of the animal study are now published in the Journal of Nutrition & Dietary Supplements.
Sixty hamsters consumed daily doses of ProAlgaZyme, its subfractions, or control via drinking water. After four weeks of supplementation, hamsters consuming the algae supplement experienced significantly increases in HDL cholesterol and significant decreases in non-HDL cholesterol compared to control. Increased expression of ApoA1 and ABCA1 confirm that the algae supplement was acting on cholesterol transport mechanisms.
The researchers concluded that more research is warranted on ProAlgaZyme and an ability to raise “good” cholesterol.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.